Selective targeting of matrix metalloproteinase inhibition in post-infarction myocardial remodeling

Journal of Cardiovascular Pharmacology

Volumn 47, Issue 2, 2006, Pages 228-235

  Apple, Kimberly A ^a   Yarbrough, William M ^a   Mukherjee, Rupak ^a   Deschamps, Anne M ^a   Escobar, Patricia G ^a   Mingoia, Joseph T ^a   Sample, Jeffrey A ^a   Hendrick, Jennifer W ^a   Dowdy, Kathryn B ^a   McLean, Julie E ^a   Stroud, Robert E ^a   O'Neill, Timothy P ^c   Spinale, Francis G ^a,b,d  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^c PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Inhibitors; Metalloproteinases; Myocardial infarction; Remodeling

Indexed keywords

COLLAGENASE 3; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; PGE 530742; STROMELYSIN; UNCLASSIFIED DRUG; PROTEINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SELECTIVITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HEART INFARCTION; HEART VENTRICLE REMODELING; MEDICAL INSTRUMENTATION; NONHUMAN; PRIORITY JOURNAL; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ECHOCARDIOGRAPHY; ENZYMOLOGY; FLUOROSCOPY; HEART MUSCLE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZATION; SWINE; TIME;

ANIMALS; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; FLUOROSCOPY; MATRIX METALLOPROTEINASES; MYOCARDIAL INFARCTION; MYOCARDIUM; PROTEASE INHIBITORS; RANDOM ALLOCATION; SWINE; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASES; VENTRICULAR REMODELING;

EID: 33746417223     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000200989.23987.b8     Document Type: Article

References (22)

1. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. 2000;101:2981-2988.
2. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res. 2002;90:520-530.
3. Nelson AR, Fingleton B, Rathenberg ML, et al. Matrix metalloproteinases: biological activity and clinical implications. J Clin Oncol. 2000;18:1135-1149.
4. Rohde LE, Ducharme A, Arroyo LH, et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation. 1999;99:3063-3070.
5. Mukherjee R, Brinsa TA, Dowdy KB, et al. Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation. 2003;107:618-625.
6. Hoekstra R, Eskens FALM, Verweij J. Matrix metalloproteinase inhibitors: current developments and future developments. Oncologist. 2001;6:415-427.
7. Wilson EM, Moainie SL, Baskin JM, et al. Region- and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodeling. Circulation. 2003;107:2857-2863.
8. Spinale FG, Coker ML, Heung LJ, et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation. 2000;102:1944-1949.
9. Lindsey ML, Gannon J, Aikawa M, et al. Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation. 2002;105:753-758.
10. Yarbrough WM, Mukherjee R, Escobar GP, et al. Selective targeting and timing of matrix metalloproteinase inhibition in post-myocardial infarction remodeling. Circulation. 2003;108:1753-1759.
11. King MK, Coker ML, Goldberg A, et al. Selective matrix metalloproteinase inhibition with developing heart failure. Effects on left ventricular function and structure. Circ Res. 2003;92:177-185.
12. McElmurray JH, Mukherjee R, New RB, et al. Angiotensin-converting enzyme and matrix metalloproteinase inhibition with developing heart failure: comparative effects on left ventricular function and geometry. J Pharmacol Exp Ther. 1999;291:799-811.
13. Deschamps AM, Yarbrough WM, Squires CE, et al. Trafficking of the membrane type-1 matrix metalloproteinase in ischemia and reperfusion: relation to interstitial membrane type-1 matrix metalloproteinase activity. Circulation. 2005;111:1166-1174.
14. Netzel-Arnett S, Mallya SK, Nagase H, et al. Continuously recording fluorescent assays optimized for five human matrix metalloproteinases. Anal Biochem. 1991;195:86-92.
15. Knight CG, Willenbrock F, Murphy G. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett. 1992;296:263-266.
16. Zempo N, Koyama N, Kenagy RD, et al. Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler Thromb Vasc Biol. 1996;16:28-33.
17. Seidler E. The tetrazolium-formazan system: design and histochemistry. Prog Histochem Cytochem. 1991;24:1-86.
18. Spinale FG, Krombach RS, Coker ML, et al. Matrix metalloproteinase inhibition during developing congestive heart failure in pigs: effects on left ventricular geometry and function. Circ Res. 1999;85:364-376.
19. Creemers EEJM, Cleutjens JPM, Smits JFM, et al. Matrix metalloproteinase inhibition after myocardial infarction. A new approach to prevent heart failure? Circ Res. 2001;89:201-210.
20. Peterson JT, Hua L. Matrix metalloproteinase inhibitor development for the treatment of heart failure. Drug Devel Res. 2000;55:29-44.
21. Ducharme A, Frantz S, Aikawa M, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest. 2000;106:55-62.
22. Hayashidani S, Tsutsui H, Ikeuchi M, et al. Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am J Physiol Heart Circ Physiol. 2003;285:H1229-H1235.